Sensex, Nifty set to open higher after four-session drop

The stock benchmarks are poised to open marginally higher on Friday, after four straight ‍sessions of losses on renewed US tariff concerns, as investors ​await a US Supreme Court ruling on the ‌legality of the levies later in the ​day.

The Gift Nifty futures were trading at 25,998.50 points as of 8:02 a.m. IST, indicating that the Nifty 50 would open above Thursday’s close of 25,876.85.

and have lost 1.7 per cent and 1.8 per cent, respectively, in the last four sessions, after US President Donald ​Trump hinted at further raising tariffs on ⁠Indian goods over New Delhi’s purchase of Russian crude.

The has already imposed of up to 50 per cent on imports from India, ​the world’s second-largest buyer ⁠of Russian oil, while New Delhi seeks to finalise a long-awaited trade deal with Washington.

Investors are waiting for a US Supreme Court ruling on the legality ‌of Trump’s tariffs. If deemed “illegal”, the U.S. government ‌could be forced to refund nearly $150 billion to importers.

Meanwhile, back home, the benchmarks could ‍find support after a sustained four-session decline, with analysts expecting buying interest around current levels.



However, a resolution of ‍the trade uncertainty and strength in domestic corporate earnings are crucial for a sustained upmove, analysts said.

Foreign portfolio investors have offloaded about $900 million worth of Indian shares in January so far, after record outflows of $19 billion in 2025.

STOCKS TO WATCH

** Reliance Industries, which operates the world’s largest refining complex, says it will consider buying Venezuelan ⁠oil if sales are permitted to non-US buyers

** Bajaj Finserve says Bajaj Group ​has acquired a 23% stake in its insurance subsidiaries from ⁠Allianz SE for 213.90 billion rupees ($2.38 billion)

** BHEL secures order worth 54 billion rupees from JV Bharat Coal Gasification & Chemicals

** Venus Remedies receives marketing authorisation in Indonesia for its antibiotic combination Ceftazidime ⁠and Avibactam

Source

Leave a Reply

Your email address will not be published. Required fields are marked *

11 + five =